Home | Locations | Contact

Toll Free: (800) 331-6634

Find a Physician

  • Provided Services

    Learn about our services

  • Patient Education

    Learn about Retinal Diseases & more

Research News

Change Text Size: A  A  A

Click Here to see the video below to hear about the first retinal chip implant performed locally by a Mid Atlantic Retina surgeon.

Research

The specialists of Mid Atlantic Retina continue to be in the forefront with their research efforts and in the development of major innovations in retina care. Mid Atlantic Retina participates in several clinical trials investigating new forms of treatment for macular degeneration, diabetic retinopathy, and a variety of other retinal conditions.

Non-exudative ("Dry") Age-related Macular Degeneration (AMD) Studies

    Enroling new patients
  • SEATTLE Sponsored by Acucela Inc.
    Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride
  • ACT MA09-hRPE-AMD-001 Sponsored by Advanced Cell Technology Inc.
    A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA 09-hRPE) Cells in Patients with Advanced Age-related Macular Degeneration (AMD).
  • ACT MA09-hRPE-SMD-001 Sponsored by Advanced Cell Technology Inc.
    A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA 09-hRPE) Cells in Patients with Stargardt’s Macular Dystrophy (SMD).
  • BAM114341 Sponsored by Glaxo-Smith-Kline.
    A phase 2, multi-centre, randomised, double-masked, placebo-controlled, parallel-group study to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GSK933776 in adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
  • CNTO 2476 Sponsored by Janssen Research and Development LLC, Cell Therapy.
    Stem Cell Study for Geographic Atrophy Phase 1/2a, Multicenter, Randomized, Dose Escalation, Fellow-Eye Controlled Study Evaluating the Safety and Clinical Response of a Single, Subretinal Administration of Human Umbilical Tissue-Derived Cells (CNTO 2476) in Subjects With Visual Acuity Impairment Associated With the Geographic Atrophy
    • Closed to enrollment
  • CFD4870g Sponsored by Genentech Inc.
    A Phase Ib/II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every Other Month to Patients With Geographic Atrophy

Neovascular (" Wet ") Age-related Macular Degeneration (AMD) Studies

    Enroling new patients
  • C-12-006. Sponsored by Alcon Research, Ltd
    A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 Versus EYLEA® in Subjects With Exudative Age-Related Macular Degeneration.
  • ATLAS. Sponsored by Wills Eye Institute.
    Optical coherence tomography guided treat and extend therapy for neovascular age related macular degeneration using aflibercept.

    Closed to enrollment
  • AREDS2. by National Eye Institute and Notal Vision, Ltd
    Home Vision Monitoring in AREDS 2 for Progression to Neovascular AMD Using the
    ForeseeHome Device
  • MD7110852 Sponsored by Glaxo Smith Kline
    A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
  • AREDSII Sponsored by NEI
    A Multi-Center, Randomized Trial of Lutein, Zeaxanthin and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in Age-related Macular Degeneration.
  • CABERNET Sponsored by Neo Vista
    A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration.
    • Completed Studies

  • E10030 for Neovascular Age-related Macular Degeneration Sponsored by Ophthotech Corporation
    A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination With Lucentis in Subjects With Neovascular Age-Related Macular Degeneration
  • HORIZON Sponsored by Genentech
    An Extension Study to Evaluate the Safety and Tolerability of Lucentis for Wet Age-related Macular Degeneration or Macular Edema Due to Retinal Vein Occlusion.
  • RADICAL Sponsored by QLT, Inc.
    A Study Comparing Combination Therapy with Reduced Fluence Visudyne (Photodynamic Therapy)-Lucentis-Dexamethasone Versus Lucentis Alone for Wet Age-related Macular Degeneration.
  • VIEW Sponsored by Regeneron
    A Study of the Efficacy and Safety of Intravitreal VEGF Trap-Eye in Subjects With Wet Age-related Macular Degeneration
  • HARBOR Sponsored by Genentech
    A Study of Ranibizumab Administered Monthly or on an As-Needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration.
  • CATT Sponsored by NEI
    Comparison of Age-Related Macular Degeneration Treatments Trials: Evaluating the Relative Efficacy and Safety of Treatment of Wet Age-related Macular Degeneration with Lucentis or Avastin.

Uveitis Studies


Enroling new patients
  • 32-007 Sponsored by Santen Inc.
    A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the eye

Closed to enrollment

  • EGP-437-004 : Sponsored by Eyegate Pharmaceuticals Inc.
    A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients with Non-Infectious Anterior Segment Uveitis


    • Completed Studies
    • C-10-034 sponsored by Alcon Research
      A Phase 3 Multicenter, Randomized, Double-Masked Study of the Safety and Efficacy of Difluprednate 0.05% Ophthalmic Emulsion Compared to Prednisolone Acetate 1% Ophthalmic Suspension in the Treatment of Endogenous Anterior Uveitis
    • Allergan Study Sponsored by Allergan
      A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate Uveitis.
    • LX211-11sponsored by Lux Biosciences, Inc
      A Multi-center, Double-Masked, Parallel Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Noninfectious Intermediate, Posterior or Pan-uveitis

    Diabetic Retinopathy Studies


    Enrolling new patients

    Closed to enrollment
    • C-01-11-008 Sponsored by Alimera Sciences Inc
      An Open Label, Multi-center Extension Study of the Safety and Utility of the New Inserter of ILUVIEN® (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg and the Safety of ILUVIEN in Subjects with Diabetic Macular Edema
    • RISE Sponsored by Genentech
      A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus.

    Completed Studies
    • ACCORD Sponsored by NHLBI and NEI
      Examining the effect of various treatments on cardiovascular disease in people with diabetes.
    • Alimera Sponsored by Alimera Sciences
      Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema.

    Central Retinal Vein Occlusion Studies


    Completed Studies
    • VEGF Trap-Eye for CRVO Sponsored by Regeneron
      A Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Due to Central Retinal Vein Occlusion.
    • CRUISE Sponsored by Genentech
      A Study of the Efficacy and Safety of Lucentis Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion.

    Branch Retinal Vein Occlusion Study


    Enrolling new patients

    Completed Studies
    • VGFTe-RVO-1027 Sponsored by Regeneron Pharmaceuticals.
      A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion
    • BRAVO Sponsored by Genentech
      A Study of the Efficacy and Safety of Lucentis Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion.

    Retinitis Pigmentosa Study


    Completed Studies

    Central Serous Chorioretinopathy


    Enrolling New Patients
    • CONTAIN Sponsored by Wills Eye Institute
      The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy.

     

    Other

    Closed to enrollment
    • TG-MV-014 Sponsored by Thrombogenetics Inc.
      A Randomized, Sham-Controlled, Double-Masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
    Completed Studies
    • GMA-OZU-10-017Sponsored by Allergan, Inc.
      A 1-Month, Multicenter, Observational Study to Evaluate the Degree of Ocular Inflammation Associated with Pars Plana Vitrectomy

    What Are Clinical Trials?

    Clinical trials are research studies in people to answer specific health questions.  Some research studies use participants with a particular illness or condition while others need healthy volunteers.

    There are five types of clinical trials: treatment, prevention, diagnostic, screening, and quality of life.  Treatment trials test new treatments and combinations of these treatments.  Prevention trials look for ways to prevent disease from occurring or returning.  Diagnostic trials seek better tests or procedures to diagnose a disease or condition.  Screening trials test the best ways to detect a disease or condition.  Quality of life trials study ways to improve quality of life in people with chronic illness.

    Clinical trials are conducted in four phases:

    • Phase 1 studies examine a new drug or treatment for the first time in people (20-80), looking at safety, proper dose, and side effects.
    • Phase 2 studies examine the effectiveness and safety of a new drug or treatment in people (100-300) with a specific disease or condition.
    • Phase 3 clinical trials, which include 1,000-3,000 people, look at the effectiveness and safety of a new drug or treatment compared to the current standard treatment or to a placebo. Subjects are randomly assigned to receive the new drug/treatment or to the standard/placebo, similar to flipping a coin.
    • Phase 4 clinical trials collect more information on a drug or treatment after its approval in the United States by the Food and Drug Administration, including the best way to use it and its risks and benefits.

    Participation in ALL clinical trials is voluntary, and you can leave a clinical trial at any time. Most clinical trials are sponsored by the federally-funded National Institutes of Health (NIH) or pharmaceutical and biotechnology companies. The NIH’s Clinicaltrials.gov Web site lists thousands of clinical trials.

    For additional information, contact our research department directly at research@midatlanticretina.com or 215-928-3092


    back to top